Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques

Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques

Author: JUCKER

Publisher: Birkhäuser

Published: 2013-03-08

Total Pages: 468

ISBN-13: 3034871368

DOWNLOAD EBOOK

Volume 36 of "Progress in Drug Research" contains 5 articles and the various indexes which facilitate its use and establish the connec tion with the previous volumes. While all articles deal with some of the topical aspects of drug research, the contribution by Robert R. Ruffolo et al. on "Drug receptors and control of the cardiovas cular system: Recent advances" is indeed in its own right a mono graphic presentation of this important domain. The remaining four reviews provide an overview of the work in volved in the search for new and better medicines, with a focus on chemical, pharmacological, toxicological, biological, biochemical and molecular modeling studies. In the 31 years this series has existed, the Editor has enjoyed the help and advice of many colleagues. Readers, the authors of the in dividual articles, and, last but not least, the reviewers have all con tributed greatly to the success of PDR. Although many comments received have been favorable, it is nevertheless necessary to analyze and to reconsider the current position and the direction of such a series. So far, it has been the Editor's aim to help spread informa tion on the vast domain of drug research, and to provide the reader with a tool helping him or her to keep abreast of the latest develop ments and trends.


Progress in Drug Research

Progress in Drug Research

Author:

Publisher: Birkhäuser

Published: 2012-12-06

Total Pages: 287

ISBN-13: 3034887353

DOWNLOAD EBOOK

Hypertension is one of the cardiovascular diseases which is most common throughout the world. It is generally defined as an elevation of systolic and/or diastolic arterial blood pressure, which is 120/80 mm Hg in normal situation. A value of 140/90 mm is generally accepted as the upper limit of normotension. Hypertension with certain risk factors such as hypercholes terolemia, diabetes, smoking and a family history of vascular disease pre disposes to arteriosclerosis and consequent cardiovascular morbidity and mortality. The treatment of hypertension leads to reduced risk of hyperten sive renal failure, haemorrhagic stroke, myocardial infarction and cardiac failure. In most cases, the cause of the hypertension can not be clearly defined. Such hypertension is termed as essential hypertension. In a few cases (5- 15%), the hypertension is secondary to definable causes, such as renal artery stenosis, a pheochromocytoma, or an endocrine disorder. This type of hyper tension is known as secondary hypertenSion. Although the exact etiology of essential hypertension is still not well known, the following factors are sup posed to play causative roles.


Improving and Accelerating Therapeutic Development for Nervous System Disorders

Improving and Accelerating Therapeutic Development for Nervous System Disorders

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2014-02-06

Total Pages: 107

ISBN-13: 0309292492

DOWNLOAD EBOOK

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.


Progress in Drug Research

Progress in Drug Research

Author: Ernst Jucker

Publisher: Springer Science & Business Media

Published: 2000

Total Pages: 330

ISBN-13: 9783764361136

DOWNLOAD EBOOK

S. Ren and E.J. Lien: CaCo-2 cell permeability vs human gastrointestinal absorption: QSPR analysis.- J.C.G. Halford and J.E. Blundell: Pharmacology of appetite suppression.- B. Olivier, W. Soudijn and I. van Wijngaarden: Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors.- D. Poyner, H. Cox, M. Bushfield, J.M. Treherne and M.K. Demetrikopoulos: Neuropeptides in drug research.- M. Kumari and M.K. Ticku: Regulation of NMDA receptors by ethanol.- H. Horikoshi, T. Hashimoto and T. Fujiwara: Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control.- Rosamund C. Smith and Simon J. Rhodes: Applications of developmental biology to medicine and animal agriculture


The Role of NIH in Drug Development Innovation and Its Impact on Patient Access

The Role of NIH in Drug Development Innovation and Its Impact on Patient Access

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2020-01-27

Total Pages: 103

ISBN-13: 0309498511

DOWNLOAD EBOOK

To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.


Basic Principles of Drug Discovery and Development

Basic Principles of Drug Discovery and Development

Author: Benjamin E. Blass

Publisher: Academic Press

Published: 2021-03-30

Total Pages: 738

ISBN-13: 0128172150

DOWNLOAD EBOOK

Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, which requires a multidisciplinary team approach with input from medicinal chemists, biologists, pharmacologists, drug metabolism experts, toxicologists, clinicians, and a host of experts from numerous additional fields. Enabling technologies such as high throughput screening, structure-based drug design, molecular modeling, pharmaceutical profiling, and translational medicine are critical to the successful development of marketable therapeutics. Given the wide range of disciplines and techniques that are required for cutting edge drug discovery and development, a scientist must master their own fields as well as have a fundamental understanding of their collaborator's fields. This book bridges the knowledge gaps that invariably lead to communication issues in a new scientist's early career, providing a fundamental understanding of the various techniques and disciplines required for the multifaceted endeavor of drug research and development. It provides students, new industrial scientists, and academics with a basic understanding of the drug discovery and development process. The fully updated text provides an excellent overview of the process and includes chapters on important drug targets by class, in vitro screening methods, medicinal chemistry strategies in drug design, principles of in vivo pharmacokinetics and pharmacodynamics, animal models of disease states, clinical trial basics, and selected business aspects of the drug discovery process. - Provides a clear explanation of how the pharmaceutical industry works, as well as the complete drug discovery and development process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property - Includes a new chapter on the discovery and development of biologics (antibodies proteins, antibody/receptor complexes, antibody drug conjugates), a growing and important area of the pharmaceutical industry landscape - Features a new section on formulations, including a discussion of IV formulations suitable for human clinical trials, as well as the application of nanotechnology and the use of transdermal patch technology for drug delivery - Updated chapter with new case studies includes additional modern examples of drug discovery through high through-put screening, fragment-based drug design, and computational chemistry


Rare Diseases and Orphan Products

Rare Diseases and Orphan Products

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2011-04-03

Total Pages: 442

ISBN-13: 0309158060

DOWNLOAD EBOOK

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.


Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance

Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance

Author: Giuseppe Di Giovanni

Publisher: Elsevier

Published: 2008-09-26

Total Pages: 682

ISBN-13: 0080932681

DOWNLOAD EBOOK

This book provides a unique and timely multidisciplinary synthesis of our current knowledge of the anatomy, pharmacology, physiology and behavioral data of the serotonin (5-HT)-dopamine (DA) interactions. Central serotonergic and dopaminergic systems play a critical role in the regulation of normal and abnormal behaviors. Moreover, recent evidence suggests that the dysfunction of the DA and 5-HT neurotransmitter systems contribute to various mental disorders including depression, schizophrenia, drug addiction and Parkinson's disease. This extremely important topic is of wide interest within the scientific community, with relevance not only to specialists but also to general practitioners and students. The book provides a valuable contribution to the debate on new pharmacological approaches for several psychopathological states, with contributions from expert neuroscientists and pharmacologists who comprehensively survey the most significant currently active areas of dopamine/serotonin interactions. - Provides an understanding of the interaction between Serotonin and Dopamine - Appeals equally to specialists, general practitioners, students and researchers - Contributes to the debate on new pharmacological approaches to several psychopathological states - Gives a comprehensive anatomical description plus the physiology and pharmacology of dopaminergic and serotonergic systems - Singles out neuropsychiatric and suggests new therapeutic approaches